Anti-CXCR2 directed therapy unmasks the potential for immunotherapy in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. Therapies targeted against stromal targets in the tumour microenvironment are now in pre-clinical and clinical trial. Here, we focus on our recent findings in autochthonous models of PDAC that suggest CXCR2 expressed on neutrophils is important in establishing immunosuppression in the primary tumour and the metastatic niche at distant sites. We discuss CXCR2 as a potential therapeutic target in the context of other potential stromal targets in PDAC.